Supplements and Featured Publications
Utilizing Antibody-Drug Conjugates and Other Novel Agents in Lung Cancer
Volume: 1
Issue: 1
Utilizing Antibody-Drug Conjugates and Other Novel Agents in Lung Cancer comprises articles and videos on experts discussing therapeutic strategies in the pipeline and on the market for their patients with non–small cell lung cancer.
On the Horizon in NSCLC: Antibody Drug Conjugates
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5